Publications by authors named "Amelia E Pearsall"
ACE-536, a recombinant protein containing a modified activin receptor type IIB, is being developed for the treatment of anemias caused by ineffective erythropoiesis, such as thalassemias and myelodysplastic syndromes. ACE-536 acts through a mechanism distinct from erythropoiesis-stimulating agents to promote late-stage erythroid differentiation by binding to transforming growth factor-β superfamily ligands and inhibiting signaling through transcription factors Smad 2/3. The goal of this Phase 1 study was to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of ascending dose levels of ACE-536 in healthy volunteers.
View Article and Find Full Text PDFPurpose: The angiogenesis inhibitor dalantercept (formerly ACE-041) is a soluble form of activin receptor-like kinase-1 (ALK1) that prevents activation of endogenous ALK1 by bone morphogenetic protein-9 (BMP9) and BMP10 and exhibits antitumor activity in preclinical models. This first-in-human study of dalantercept evaluated its safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity in adults with advanced solid tumors.
Experimental Design: Patients in dose-escalating cohorts received dalantercept subcutaneously at one of seven dose levels (0.
Introduction: ACE-031 is a soluble form of activin receptor type IIB (ActRIIB). ACE-031 promotes muscle growth by binding to myostatin and other negative regulators of muscle mass.
Methods: This double-blind, placebo-controlled study evaluated the safety, pharmacokinetics, and pharmacodynamics of ACE-031 in 48 healthy, postmenopausal women randomized to receive 1 dose of ACE-031 (0.
Article Synopsis
- * In a follow-up study with female cynomolgus monkeys, those treated with ACE-011 showed significant increases in bone mineral density (BMD) and trabecular bone volume compared to the control group.
- * The results suggest that ACE-011 could be a promising treatment for preventing or treating issues related to skeletal fragility in humans.
Article Synopsis
- A study evaluated the effects of ACE-011 on safety, pharmacokinetics, and bone biomarkers in healthy postmenopausal women, showing it increases bone formation markers and reduces bone resorption markers.
- ACE-011 is a fusion protein that prevents activin from binding its receptors, with a randomized, placebo-controlled trial indicating it is safe and well-tolerated, with no serious adverse events reported.
- The findings highlight ACE-011's potential as a treatment for diseases associated with bone loss due to its ability to enhance bone formation and decrease resorption.